Evaluation of CYP2C9 Activity

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9.

The purpose of the present study is:

1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity

2. To correlate phenytoin metabolic ratio with CYP2C9 genotype

3. To study the frequency distribution of CYP2C9 activity in-vivo

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hadassah Medical Organization
• Collaborator: United States - Israel Binational Science Foundation
• Treatments: Phenytoin

Criteria

Inclusion Criteria:

• Age range of 20-50 years old

• Absence of significant disease states

Exclusion Criteria:

• The presence of significant disease states

• The use of drugs (including birth control pills)